浜у搧璇存槑
涓€鑸弿杩?/p>
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as CD4+/CD56+ hematodermic neoplasm or blastic NK-cell lymphoma, is a malignant neoplasm composed of immature hematopoietic precursors of plasmacytoid dendritic cells. The most frequent manifestation is a skin lesion, bone marrow involvement, and regional lymphadenopathy. Myeloid leukemia cutis (LC), myeloid sarcoma, and large aggressive B cell lymphomas should be differentiated from BPDCN. Recently, it has been reported that these entities can be distinguished by using immunohistochemistry (IHC) in paraffin-embedded tissue sections. In this study, 23 myeloid LC and 12 BPDCN cases were evaluated using a panel of antibodies against CD123, TCL1, CD4, CD56, MPO and CD33; with results as follows: anti-CD123 stained 4 cases (17%) of myeloid LC and 10 cases (83%) of BPDCN; anti-TCL-1 stained 2 cases (9%) of myeloid LC and 9 (82%) of 11 cases of BPDCN; anti-CD4 stained 2 cases (9%) of LC and all 12 cases (100%) of BPDCN; anti-CD56 stained 12 cases (52%) of LC and all 12 cases (100%) of BPDCN; anti-myeloperoxidase stained 7 cases (30%) of LC and 0 cases (0%) of BPDCN. Anti-CD33 was not helpful; it stained 18 (78%) cases of LC and 11 cases (92%) of BPDCN. The results indicated that a panel that includes antibodies against CD4, CD56, CD123, and TCL-1 can appropriately distinguish between myeloid LC and BPDCN.
CD123 IHC expression has been studied in 157 acute myeloid leukemia (AML) bone marrow biopsies and/or marrow particle preparations, and correlated with the morphologic, immunophenotypic, and cytogenetic features and with the presence of FLT3-ITD and NPM1 mutations. CD123 IHC expression has been seen in 40% of AML, across a wide spectrum of 2008 World Health Organization subtypes and was most frequent within the intermediate risk group. Compared with CD123 IHC negative AML, CD123 IHC positive AML demonstrated higher marrow blast percentages (median 69%), monocytic differentiation (33/63 cases), and CD34 negativity (29/63 cases). 83% (25/30) FLT3-ITD-mutated AML were CD123+ and 62% (18/29) NPM1-mutated cases were CD123 IHC+ (P=0.0052). CD123 IHC+AML presents with characteristic pathologic features, some of which may be related to underlying FLT3-ITD and/or NPM1 mutations.
璐ㄩ噺
 IVD |
 IVD |
 IVD |
 RUO |
鑱旂郴
CD123 Positive Control Slides, Product No. 198S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
澶栧舰
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
鍒跺璇存槑
Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.
Download the latest released IFU
Note: This IFU may not apply to your specific product lot.
鍏朵粬璇存槑
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
娉曞緥淇℃伅
Cell Marque is a trademark of sigma-aldrich Co. LLC
鍩烘湰淇℃伅
| NACRES | NA.41 |
浜у搧鎬ц川
| 璐ㄩ噺姘村钩 | 500 100 |
| 鐢熺墿鏉ユ簮 | mouse |
| 鍋惰仈鐗?/td> | unconjugated |
| 鎶椾綋褰㈠紡 | culture supernatant |
| antibody product type | primary antibodies |
| 鍏嬮殕 | 6H6, monoclonal |
| 鎻忚堪 | For In Vitro Diagnostic Use in Select Regions (See Chart) |
| 褰㈠紡 | buffered aqueous solution |
| species reactivity | human |
| 鍖呰 | vial of 0.1 mL concentrate (198M-14) vial of 0.5 mL concentrate (198M-15) bottle of 1.0 mL predilute (198M-17) vial of 1.0 mL concentrate (198M-16) bottle of 7.0 mL predilute (198M-18) |
| manufacturer/tradename | Cell Marque? |
| technique(s) | immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100 |
| 鍚屼綅绱?浜氬瀷 | IgG1κ |
| 鎺у埗 | blastic plasmacytoid dendritic cell neoplasm |
| 杩愯緭 | wet ice |
| 鍌ㄥ瓨娓╁害 | 2-8鈩傸/td> |
| 鍙鍖朁/td> | cytoplasmic |
瀹夊叏淇℃伅
| 鍌ㄥ瓨鍒嗙被浠ｇ爜 | 12 - Non Combustible Liquids |
| WGK | WGK 2 |
| 闂偣(F) | Not applicable |
| 闂偣(C) | Not applicable |
m.cnreagent.com
